Evaluation of efficacy and anti-inflammatory action of PlacentrexTM in women with inflammatory Pap smears.

Evaluation of efficacy and anti-inflammatory action of PlacentrexTM in women with inflammatory Pap smears

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2010/091/000197

Enrollment

150

Registered

2010-04-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- To evaluate the efficacy and anti inflammatory action of Placentrex in women with inflammatory Pap smears.

Interventions

Intervention1: PLACENTREX: PLACENTREX INJECTION FOR 21 DAYS Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: PAP SMEAR SHOWING INFLAMMATION ABILITY TO GIVE INFORMED CONSENT SEXUALLY ACTIVE NO DEBILITATING DISEASE

Exclusion criteria

Exclusion criteria: OBVIOUS GROWTH PREVIOUS PROCEDURES, EG. EXCISION BIOPSY,CRYOTHERAPY AND CONISATION AND HYSTERECTOMY ACUTE CERVICITIS AND VAGINITIS PREGNANCY SEVERE DEBILITATING DISEASE

Design outcomes

Primary

Measure	Time frame
repeat normal pap testTimepoint: Resolution of inflammatory Pap smear	—

Secondary

Measure	Time frame
Resolution of inflammatory Pap smearTimepoint:	—

Countries

India

Contacts

Public ContactNEERJA BHATLA

neerjabhatla@rediffmail.com01126594991

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026